doi:10.1177/0748233709348393 Islam, M.T., Mishra, S.K., Tripathi, S., de Alencar, M.V.O.B., e Sousa, J.M.d.C., Rolim, H.M.L., de Medeiros, M.d.G.F., Ferreira, P.M.P., Rouf, R., Uddin, S.J., Mubarak, M.S
According to the UK product information, these include: Nausea (very common, affecting more than 1 in 10 people) Diarrhoea and constipation (very common) Vomiting and abdominal pain (common) Reduced appetite and indigestion (common) Flatulence and bloating (common) These symptoms are generally mild to moderate and tend to improve as the body adjusts to the medication
This pattern allows some recovery while maintaining regenerative stimulus
Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials
C.AtkinS
Efficacy and weight change are approximate averages from clinical trials